Tag: RNN

Blue Horseshoe Stocks: CNDO Recap & Much More

Esperion Therapeutics, Inc. ESPR

ESPR was an unstoppable juggernaut for us this week. On Tuesday, we floated the idea of tracking the ESPR 04/17 $90 Calls, and those contracts have gone on a wild run since then.

As the stock pushed its way to new 52-week highs yesterday, finally topped those contracts out at 28.50, it marked an overall increase of 714% from the 3.50 low we observed on Tuesday; quite an impressive feat for a span of just three sessions.

Add in the multiplicity of opportunities in short-term weekly calls that we’ve witnessed (on the order of percentage gains in the thousands!) as the stock made this historical run, and we’ll have to mark ESPR down as one of our most successful alerts thus far in 2015.

Coronado BioSciences, Inc. CNDO

CNDO did quite well following our tag of it in yesterday morning’s extended watchlist, further solidifying the notion that biopharmas have been on a real hot streak this week.

We watched as CNDO ripped its way from a daily low of 3.62 to as high as 5.35, totaling an intraday run of 48% The move came on volume which smashed the 3-month average by a factor of more than 32X Congrats to any of our readers who lassoed this momentum-mover for some tidy gains yesterday!

Amicus Therapeutics, Inc. FOLD

FOLD also appear on yesterday’s watchlist before extending its own epic run with a modest yet notable increase of 13% on the day, trading a range from 11.63-13.20. Like the previously mentioned play, this stock has also been on a blue-sky breakout, setting new annual highs with every uptick.

Morning Gappers – Options Ideas

Nike, Inc. NKE shares surged as the company beat Wall St. estimates for profits on yesterday’s earnings call, and appears to be gapping up significantly in this morning’s premaket activity. We are going to be monitoring the $101-104 Weekly Calls for potential daytrading opportunities, and for a possible a swing trade into the weeks ahead, we’ll radar the 04/10 $105-110 Calls.

Prothena Corp plc PRTA is gapping up monstrously today to the tune of 40%, soaring on yesterday’s post-market revelation of positive Phase 1 results for its treatment for Parkinson’s disease. We will be placing $35 and 40 Calls on watch for daytrading potential, while tracking the 06/19 $45 Calls for a longer-term play.

Extended Watchlist:
VBLT, SPEX, VGGL, ICLD, RNN

Blue Horseshoe Stocks: NQ Review & More

NQ Mobile, Inc.  NQ

Our coverage of NQ stretches all the way back to the Fall of 2013 when the stock made a huge run, and we tracked it to a similar albeit smaller-scale spike in October, so we are quite familiar with this play. We have good reason to re-assess NQ this morning in the wake of an interesting PR, coupled with a good positioning of the chart.

In terms of the NQ chart, there a couple of finer points that we’ll point out on the following snapshot:

This morning’s PR relates to a big open market stock repurchase by management which seems to be fueling NQ in the premarket. >>> VIEW PR  


Cannabis Coverage:

A few of the marijuana-related stocks we were mentioning yesterday morning managed to put up some solid numbers over the course of the day.

CBIS traded in a range from .068-.08 (+17%) on roughly 4X its monthly average volume.

MCIG did slightly better as recorded a 19% move from .15 to .178, trading more than twice its average volume.

EAPH also had a heavy volume day to the tune of roughly 3X its average, and made a healthy jump of 21% as it traded from its open at .024 to a high of .029.

As medical and recreational marijuana acceptance continues to spread, we’ll need to keep a close eye on these and many other cannabis plays, as we tend to believe that growth in this arena will be more substantial in 2015 than any previous year.

A few other pot plays to watch this week: WDHR, NRTI, MDCN, LATF, VPOR

Extended Watchlist:
CYTR, NERV, FRO, CPST, DARA, MNK, SNSS, RNN

Blue Horseshoe Stocks: LPCN Recap, LPDX & More

Lipocine, Inc. LPCN

LPCN served up an opportunity at some decent intraday gains after appearing on yesterday morning’s extended watchlist.

The stock played out a classic dip and rip scenario, falling to a morning low of 6.89 before surging back in the afternoon to a subsequent high of 8.42. That offered traders a chance at intraday gains of up to 22% on plenty of liquidity- the stock would trade 23.5X its 30-day average volume.

The productive session came on the heels of the company announcing favorable results from Phase-3 clinical testing of “LPCN 1021”, its oral treatment for low testosterone >>> VIEW PR

LipoScience, Inc. LPDX

LPDX is gapping up heavily in the premarket, and the interesting story behind it is one that we’re definitely going to want to give our close attention. Early this morning, the company announced that it was the subject of a buyout that would be executed at a share price of $5.25. Barely an hour later, another PR hit the LPDX newswire, concerning an investigation of the managerial board’s handling of the deal, and whether or not they have secured the best possible buyout price.

According to the investigative firm leading the case, “The $5.25 per share acquisition price is far less than where the stock has recently traded. In fact, on January 25, 2013, LipoScience stock opened for trading at $9.75 the day the Company sold 5.0 million shares of stock in its initial public stock offering.” >>> VIEW PR

The playing out of this scenario is going to be an interesting story moving forward, which is why we wanted to flag LPDX this morning, and fill everyone in on this morning’s happenings. The possibility that the investigation could lead to a potential restructuring of the buyout is enough to have us keep our ears to the tracks on this one for the foreseeable future.

Magnum Hunter Resources Corp. MHR

MHR is another morning gapper that we’re putting on our radars. This morning Magnum announced impressive throughput volumes on its “Eureka Hunter” gas gathering pipeline. According to the CEO, “increased capacity has resulted in a record day of approximately 316,500 MMBtu of natural gas”. >>> VIEW PR

Options Trading Idea: PBR Calls 

We’re interested in the PBR October 31st $15.50 Calls  last traded at 1.88. If we can see PBR make its way back to recent $20+ highs within a month, it could put us in position to see returns of up to 150-200% on those contracts.

Extended Watchlist:
 RNN, MNKD, CNET, VHC, MPET